For eligible patients with HR+/HER2-low (IHC 1+ or IHC 2+/ISH–) mBC who have received at least 1 line of ET in the metastatic setting1

ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer.